COMMUNIQUÉS West-GlobeNewswire

Option Care Health to Participate in the Bank of America Health Care Conference
04/05/2026
BANNOCKBURN, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
04/05/2026
MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer [...]
Biodesix Announces First Quarter 2026 Results and Highlights
04/05/2026
Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conference Call and [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/05/2026
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly- [...]
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
04/05/2026
– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome- [...]
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
04/05/2026
Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat data in [...]
Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
04/05/2026
Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will report [...]
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
04/05/2026
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it [...]
Janell Rae Releases Debut Book Satori: Awakening to Your Truest Self Through Energy Intelligence
05/05/2026
After 25 years of transformative client work, Janell Rae brings her complete Energy Intelligence Method™ to readers for the first time — offering a direct path back to the most authentic version of themselves. Silver [...]
Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
04/05/2026
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous [...]
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
04/05/2026
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of [...]
Kyntra Bio to Report First Quarter 2026 Financial Results
04/05/2026
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on [...]
CooperCompanies Appoints Paul Keel to its Board of Directors
04/05/2026
SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director [...]
Elite Pro Force Male Enhancement Gummies Claims Evaluated: The Ultra Peak Horse Gelatin Trick for Men
04/05/2026
How Elite Pro Force Male Enhancement Gummies Ingredients, Blood Flow Claims, and Non-Prescription Male Vitality Support Work in 2026 Chicago, IL, May 04, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated [...]
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
04/05/2026
$55 million funded at closing to repay existing loan facility THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility [...]
Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance
04/05/2026
First quarter revenue growth of 1.6% First quarter diluted EPS of $(0.39); adjusted diluted EPS of $0.10 First quarter operating cash flow of $12.8 million MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Inspire Medical [...]
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
04/05/2026
HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
04/05/2026
PARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand [...]
InspireMD Reports First Quarter 2026 Financial Results
04/05/2026
- Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro protection system for [...]

Pages